RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Human Metabolome Technologies Debt 2024

Human Metabolome Technologies Debt

-1,430.27 JPY

Human Metabolome Technologies Dividend yield

1.56 %

Ticker

6090.T

ISIN

JP3794530000

In 2024, Human Metabolome Technologies's total debt was -1,430.27 JPY, a 12.48% change from the -1,271.55 JPY total debt recorded in the previous year.

Human Metabolome Technologies Aktienanalyse

What does Human Metabolome Technologies do?

Human Metabolome Technologies Inc (HMT) is a Japanese company specializing in the research and development of metabolome analysis. HMT was founded in 2000 with the vision of gaining a deeper understanding of the metabolic processes of the human body in order to contribute to better healthcare. HMT's business model involves conducting metabolome analysis using mass spectrometry and other technologies to characterize the body's metabolic processes. This includes analyzing both healthy and diseased metabolism from samples such as blood, urine, or tissue in large numbers to identify biomarkers or signatures that can be used in the early detection, diagnosis, prognosis, and treatment of diseases. In this sense, HMT serves as an important partner for researchers in the pharmaceutical and biomedical industry who want to develop new diagnostic and therapeutic approaches. In recent years, HMT has developed a wide range of metabolome analysis technologies tailored to various applications. One of HMT's most important products is the Targeted Metabolomics Platform, which allows for the quantification of a variety of metabolites in samples such as blood or urine. This is an important step towards developing biomarkers that can serve as indicators of an organism's metabolic state. Another important platform of HMT is the Biomarker Discovery Platform, which specializes in the identification of biomarkers associated with specific diseases. This platform is often used by pharmaceutical companies to develop new drugs tailored to the specific needs of patients with certain diseases. HMT has also developed a comprehensive metabolome database that allows researchers and analysts to compare their own data with a variety of reference data. This database contains information on thousands of metabolites and allows researchers to better understand metabolic pathways and biomolecular interactions. In recent years, HMT has also increased its investment in clinical research to explore the potentials of metabolome analysis in the diagnosis and treatment of cancer, diabetes, cardiovascular diseases, metabolic disorders, and other diseases. In collaboration with clinics and universities, HMT has conducted several clinical studies to evaluate the effectiveness of metabolome analysis in the early detection and monitoring of diseases. HMT is headquartered in Tsuruoka, Japan, and is also active in the US, Europe, and Asia. The company employs over 100 people and has become a leading provider of metabolome analysis and services. In summary, HMT has developed unique expertise in the field of metabolome analysis and is able to offer a wide range of products and services to support researchers and analysts in the study of the metabolic processes of the human body. With a strong emphasis on innovation and clinical research, HMT will continue to play an important role in the development of new diagnostic and therapeutic approaches tailored to the specific needs of patients. Human Metabolome Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Human Metabolome Technologies's Debt Structure

Human Metabolome Technologies's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Human Metabolome Technologies's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Human Metabolome Technologies’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Human Metabolome Technologies’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Human Metabolome Technologies Stock

What is the debt of Human Metabolome Technologies this year?

Human Metabolome Technologies has a debt level of -1,430.27 JPY this year.

What was the debt of Human Metabolome Technologies compared to the previous year?

The debt of Human Metabolome Technologies has increased by 12.48% compared to the previous year increased.

What are the consequences of high debt for investors in Human Metabolome Technologies?

High debt can pose a risk for investors of Human Metabolome Technologies, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Human Metabolome Technologies?

Low debt means that Human Metabolome Technologies has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Human Metabolome Technologies affect the company?

An increase in debt of Human Metabolome Technologies can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Human Metabolome Technologies affect the company?

A reduction in debt of Human Metabolome Technologies can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Human Metabolome Technologies?

Some factors that can influence the debt of Human Metabolome Technologies include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Human Metabolome Technologies so important for investors?

The debts of Human Metabolome Technologies are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Human Metabolome Technologies take to change the debt?

To change the debt, Human Metabolome Technologies can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Human Metabolome Technologies pay?

Over the past 12 months, Human Metabolome Technologies paid a dividend of 10 JPY . This corresponds to a dividend yield of about 1.56 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 10 JPY.

What is the dividend yield of Human Metabolome Technologies?

The current dividend yield of Human Metabolome Technologies is 1.56 %.

When does Human Metabolome Technologies pay dividends?

Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Human Metabolome Technologies?

Human Metabolome Technologies paid dividends every year for the past 0 years.

What is the dividend of Human Metabolome Technologies?

For the upcoming 12 months, dividends amounting to 10 JPY are expected. This corresponds to a dividend yield of 1.56 %.

In which sector is Human Metabolome Technologies located?

Human Metabolome Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Human Metabolome Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Human Metabolome Technologies pay the last dividend?

The last dividend was paid out on 9/1/2024.

What was the dividend of Human Metabolome Technologies in the year 2023?

In the year 2023, Human Metabolome Technologies distributed 0 JPY as dividends.

In which currency does Human Metabolome Technologies pay out the dividend?

The dividends of Human Metabolome Technologies are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Human Metabolome Technologies

Our stock analysis for Human Metabolome Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Human Metabolome Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.